Despite the heterogeneous results, these studies highlight the biological and therapeutic rationale of ATRA in NPM1-mutated AML, supporting the continued investigation of ATRA/ATO-based strategies, possibly in combination with other targeted therapies, in this AML molecular subtype. Here, NPM1 is linked to acute myeloid leukemia.